B+
Bull case
0%
Probability
Target price
$31.00
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
IMNM
ImmunomeDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The RINGSIDE efficacy results and accepted NDA support a potential varegacestat approval; IM-1021 data and newly IND-cleared IM-1340 offer additional, less-proven pipeline options. [#SEC-8K-2026-08-11] [#IR-2026-09-30]
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -14.1.
What can break
Early-stage ADC and radioligand programs face enrollment, safety and efficacy risk; IM-1340 preclinical activity may not translate to patients. [#IR-2026-09-30]
Momentum
4
Value
41
Sentiment
68
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $19.50 · Bull $31.00 · Bear $12.00Analysis 2026-10-02; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-26 • Vendor: Data Vendor v1
Scores
As of 2026-10-26 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-02 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-26
Investment thesis
As of 2026-10-26
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-26. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $35.33
Why
Momentum4 · Δ7d +2.0
Value41 · Δ7d -0.0
Sentiment68 · Δ7d -14.1
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta -14.1.
Contradictions & invalidation
- • Early-stage ADC and radioligand programs face enrollment, safety and efficacy risk; IM-1340 preclinical activity may not translate to patients. [#IR-2026-09-30]
- • Immunome reported $520.0 million in cash, equivalents and marketable securities at June 30, 2026 and expected funding into 2028, while Q2 R&D expense was $59.9 million. Spending and future financing needs warrant monitoring. [#PR-EARNINGS-2026-08-11]
- • Regulatory, clinical and launch outcomes remain uncertain.
Catalyst clock
2026-12-31
IM-1340 Phase 1 initiation
Lead driver: Sentiment · See AI snapshot
Momentum
4
8% active weight
Current posture
7d trendFlat
Δ7d
+2.0
Δ21d
-19.5
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
-0.4
Sentiment
68
45% active weight
Current posture
7d trendSoftening
Δ7d
-14.1
Δ21d
+8.2
Why this grade
Composite grade D. Momentum 4.4 / Value 40.6 / Sentiment 68.1
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-02. Scenario method
Most likely
B
Base case
0%
Probability
Target price
$19.50
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
B-
Bear case
0%
Probability
Target price
$12.00
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-26
Fundamentals (TTM)
As of 2026-10-26
Market Cap
$2.11B
Beta
2.33
Shares Out
118M
P/E (TTM) · Derived
-7.4
P/S (TTM)
224.68
P/FCF (TTM) · Derived
-8.36
Rev YoY
-100.0%
EPS YoY
+29.4%
Gross Margin
+25.7%
Op Margin
-2419.9%
Net Debt
-$649.63M
Current Ratio
15.08
As of 2026-10-26 • Updated nightlySource: Internal modelMethods & Data